Market Place
Sourcing Support
ALX Oncology Reports Q2 2024 Results And Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Elevation Oncology Reports Q2 2024 Results And Achievements
06 Aug 2024 //
PR NEWSWIRE
The China NMPA Approved CYRAMZA for the Treatment of Hepatocellular Carcinoma
09 Oct 2022 //
PRNEWSWIRE
Eli Lilly`s Biologic Cyramza (Ramucirumab) Receives Approval in the U.S.
22 Mar 2022 //
FDA
Pieris Pharma Announces First Patient Dosed Phase 2 Gastric Cancer
14 Jan 2022 //
TRIALSITENEWS
Edesa finds a signal in severely ill Covid-19 patients
21 Sep 2021 //
EVALUATE
Lilly 483 report offers insights from site making COVID antibodies
12 Aug 2021 //
RAPS
FDA issues form 483 to Eli Lilly
12 Aug 2021 //
FDA
Eli Lilly`s Biological Ramucirumab Receives Supplemental Approval In US
17 Jun 2021 //
FDA
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 in Combinations
10 Jun 2021 //
BIOSPACE
Basilea announces Clinical Trial Collb and Supply Agreement with Eli Lilly
27 Oct 2020 //
GLOBENEWSWIRE
PIERIS & LILLY ENTER INTO A CLINICAL TRIAL COLLABORATION TO EVALUATE OF PRS-343
10 Aug 2020 //
PRESS RELEASE
Eli Lilly`s Cyramza (Ramucirumab) Receives Supplemental Approval in US
08 Jul 2020 //
FDA
Lilly`s Cyramza, after split decision from FDA, wins first-line lung cancer nod
02 Jun 2020 //
FIERCE PHARMA
Lilly`s CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment
29 May 2020 //
PRNEWSWIRE
Chuffed on new launches, Eli Lilly unveils Street-beating 2020 sales forecast
19 Dec 2019 //
FIERCE PHARMA
Eli Lilly`s Cyramza (Ramucirumab) Receives Supplemental Approval in US
07 Nov 2019 //
FDA
Eli Lilly`s Cyramza (Ramucirumab) Receives Supplemental Approval in US
03 Aug 2019 //
FDA
Roche, Merck, Novartis and others hike prices on 83 meds starting in July
10 Jul 2019 //
FIERCE PHARMA
AZ bags two extensions in latest CHMP decisions
01 Jul 2019 //
PHARMATIMES
Bristol-Myers Squibb’s Opdivo misses its shot at earlier use in liver cancer
25 Jun 2019 //
FIERCE PHARMA
Eli Lilly`s Cyramza (Ramucirumab) Receives Supplimental Approval In US
13 May 2019 //
FDA
Lilly scores targeted liver cancer win for Cyramza
13 May 2019 //
FIERCE PHARMA
US FDA approves Lilly`s Cyramza to treat patients with hepatocellular carcinoma
13 May 2019 //
PHARMABIZ
With Alimta patent cliff looming, Lilly plots stronger foothold in NSCLC Cyramza
13 Mar 2019 //
ENDPTS
Drugs targeting metastatic cancers available through AllianceRx Walgreens Prime
13 Feb 2019 //
PR NEWSWIRE
Eli Lilly`s Ramucirumab Receives Supplemental Approval in US
28 Nov 2018 //
FDA
Eli Lilly`s Biological Ramucirumab Receives Approval in US
26 Nov 2018 //
FDA
Eli Lilly`s Biological Cymraza (Ramucirumab) Receives Approval in US
17 Aug 2018 //
FDA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.